FOXA1 and prostate carcinoma: “PanCancer” panel (FOXA1, RARβ2, and RASSF1A) detected cancer with 64.3% sensitivity, 69.8% specificity and 66.4% accuracy. “CancerType” panel (GSTP1 and SOX17) discriminated between lung and prostate cancer with 93% specificity.